Rethinking Clinical Trials

JANUARY 17, 2024

The first drug that used the new process was Remdesivir in May 2020. UPMC set clear criteria based on the published data at the time for who could and could not receive Remdesivir. UPMC established weighted factors for the Remdesivir lottery that were established by the ethics and clinical committee.

Clinical Trials 169

Clinical Trials Clinical Trials Antibody Trials 169

The Pharma Data

MARCH 23, 2022

Back in 2018, researchers tested a broad-spectrum antiviral candidate called remdesivir/VEKLURY, which acts as a nucleotide decoy to get incorporated into the viral RNA genome and stop viral polymerase. But targeting Ebola virus polymerase has proven tough. A new route for interfering with Ebola virus infection.

Protein 52

Protein Genome Genomics Research 52

pharmaphorum

OCTOBER 29, 2021

COVID-19 therapy Veklury (remdesivir) continued to lead the charge at Gilead with a massive $1.9 The post Gilead tags Merck for first-line triple negative breast cancer trial appeared first on. billion in sales during the three-month period – way ahead of projections – with turnover expected to reach up to $4.8

Trials 52

Trials Sales FDA Approval Production 52

The Pharma Data

MAY 4, 2021

billion, primarily driven by Pfizer CentreOne, Pfizer’s contract manufacturing operation, reflecting sales of legacy Upjohn products to Viatris (4) and remdesivir to Gilead Sciences Inc., Hospital products, which grew 10% operationally to $2.3 down 7%, which reflects relatively stable U.S. View source version on businesswire.com : [link].

Vaccination 40

Vaccination Vaccine Production Sales 40